Rein Therapeutics (RNTX) Net Equity Issued and Repurchased (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Net Equity Issued and Repurchased of $354000.0 for Q1 2026, down 51.97% year-over-year from $737000.0 in Q1 2025, and down 75.62% quarter-over-quarter from $1.5 million in Q4 2025.
Rein Therapeutics (RNTX) Net Equity Issued and Repurchased (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Net Equity Issued and Repurchased for 7 consecutive years, with $354000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased fell 51.97% year-over-year to $354000.0; the TTM figure through Mar 2026 stood at $1.4 million (down 87.38% YoY), while the FY2025 annual figure was $1.8 million, down 82.91% from the prior year.
- Net Equity Issued and Repurchased eased to $354000.0 in Q1 2026 per RNTX's latest filing, from $1.5 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $10.9 million in Q2 2024 and bottomed at -$370000.0 in Q2 2025.
- Historically, Net Equity Issued and Repurchased has averaged $2.1 million across 3 years, with a median of $545500.0 in 2025.
- Annual changes were most pronounced in 2025 — Net Equity Issued and Repurchased slumped 103.38% — and 2026, when it plunged 51.97%.
- Rein Therapeutics' Net Equity Issued and Repurchased stood at -$292000.0 in 2024, then soared by 597.26% to $1.5 million in 2025, then sank by 75.62% to $354000.0 in 2026.
- Business Quant data shows RNTX's Net Equity Issued and Repurchased at $354000.0 in Q1 2026, $1.5 million in Q4 2025, and -$370000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 53.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.19 Mn |
| Jun 30, 2026 | 53.19 Mn |
| Mar 31, 2026 | 354,000.00 |
| Mar 31, 2026 | 354,000.00 |
| Dec 31, 2025 | 1.45 Mn |
| Dec 31, 2025 | 1.45 Mn |
| Jun 30, 2025 | -370,000.00 |
| Jun 30, 2025 | -370,000.00 |
| Mar 31, 2025 | 737,000.00 |
| Mar 31, 2025 | 737,000.00 |
| Sep 30, 2024 | -292,000.00 |
| Sep 30, 2024 | -292,000.00 |
| Jun 30, 2024 | 10.94 Mn |
| Jun 30, 2024 | 10.94 Mn |
| Mar 31, 2021 | 59.04 Mn |
| Mar 31, 2021 | 59.04 Mn |
| Jun 30, 2020 | 11.18 Mn |
| Jun 30, 2020 | 11.18 Mn |
| Sep 30, 2017 | -1,000.00 |
| Sep 30, 2017 | -1,000.00 |